Skip to content
ChickenStockChickenStock
ResearchCTKB
Cytek Biosciences logo

Cytek Biosciences (CTKB) stock

NASDAQ

$5.83+5.53%(+0.31)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-9.30x

Net loss — not comparable

P/B

2.38x

P/S

3.69x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 1.9% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 4, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

25 SEC filings
  • Jiang WenbinPRESIDENT AND CEO · Aug 18, 2026Shares withheld for taxes36,269 shares · $169K
    Avg. price $4.67
    Show 4 price lots
    • 20,956 shares × $4.67$98K
    • 7,062 shares × $4.67$33K
    • 5,382 shares × $4.67$25K
    • 2,869 shares × $4.67$13K
  • McCombe William D.Chief Financial Officer · Aug 18, 2026Shares withheld for taxes11,904 shares · $56K
    Avg. price $4.67
    Show 3 price lots
    • 5,401 shares × $4.67$25K
    • 4,392 shares × $4.67$21K
    • 2,111 shares × $4.67$10K
  • Yan MingCHIEF TECHNOLOGY OFFICER · Aug 18, 2026Shares withheld for taxes8,088 shares · $38K
    Avg. price $4.67
    Show 4 price lots
    • 3,463 shares × $4.67$16K
    • 1,778 shares × $4.67$8K
    • 1,501 shares × $4.67$7K
    • 1,346 shares × $4.67$6K
  • Yan MingCHIEF TECHNOLOGY OFFICER · Aug 18, 2026Option exercise33,270 shares
    Show 4 price lots
    • 7,363 sharesValue not reported
    • 5,525 sharesValue not reported
    • 6,162 sharesValue not reported
    • 14,220 sharesValue not reported
  • MUIR GLENN PDirector · Aug 18, 2026Option exercise3,086 shares
    3,086 shares held after
  • Jiang WenbinPRESIDENT AND CEO · Aug 18, 2026Option exercise120,095 shares
    Show 4 price lots
    • 29,002 sharesValue not reported
    • 22,100 sharesValue not reported
    • 11,781 sharesValue not reported
    • 57,212 sharesValue not reported
  • McCombe William D.Chief Financial Officer · Aug 18, 2026Option exercise35,420 shares
    Show 3 price lots
    • 6,320 sharesValue not reported
    • 13,051 sharesValue not reported
    • 16,049 sharesValue not reported
  • Holder MichaelDirector · Aug 18, 2026Option exercise2,181 shares
    62,875 shares held after
  • Chin RichardDirector · Aug 18, 2026Option exercise6,107 shares
    28,499 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Cytek Biosciences (CTKB) stock information

NASDAQ

Cytek Biosciences (CTKB) is listed on NASDAQ. Its market capitalization is about $763M. On trailing-twelve-month earnings the P/E ratio is -9.3, and the P/B ratio is 2.38. Return on equity is -25.5%. These figures are computed in-house from official filings and are reference information only.

Cytek Biosciences — frequently asked questions

What is the P/E ratio of Cytek Biosciences (CTKB)?
On a trailing-twelve-month basis, CTKB trades at a P/E ratio of -9.3. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Cytek Biosciences?
CTKB has a market capitalization of about $763M. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.